ARVIND REMEDIES LIMITED  
    ARVIND REMEDIES LIMITED  
    Registered Office : 190, Poonamalle High Road, Chennai - 600 084  
    AUDITED FINANCIAL RESULTS  
    FOR THE YEAR ENDED MARCH 31, 2007  
      (Rupees in Lakhs.)  
      Particulars Nine Months ended 31.12.2006 Three months ended 31.03.2007 Three months ended 31.03.2006 Year ended 31.3.2007 Year ended 31.3.2006    
        Unaudited Unaudited Unaudited Audited Audited    
      Gross Sales          12,906.27           5,066.66            4,221.04        17,972.93   16,507.79      
      Less: Excise Duty          (1,612.12)             (702.31)              (563.41)        (2,314.43)    (2,117.19)      
      Net Sales         11,294.15           4,364.35            3,657.63        15,658.50   14,390.60      
      Other Income                16.37                  5.21                   8.18               21.58          66.10      
      Total Income         11,310.52           4,369.56            3,665.81        15,680.08   14,456.70      
                       
      Total expenditure :                
      a)  (Increase) / Decrease in Stock                31.30             (331.98)               356.96           (300.68)        423.05      
      b)  Materials Consumed           9,471.37           4,176.26            3,027.27        13,647.63   12,012.64    
      c)  Staff Cost              249.97                90.45                 63.19             340.42        293.97    
      d)  Other expenditure              465.10              153.03                 37.53             618.13        597.78    
      Total (a) to (d)         10,217.74           4,087.76            3,484.95        14,305.50   13,327.44      
                       
      Gross Profit before Interest & Depreciation           1,092.78              281.80               180.86          1,374.58     1,129.26      
      Interest              426.07              229.11               142.63             655.18        476.20      
      Depreciation              127.14                42.98                 37.61             170.12        151.25      
                       
      Profit before Tax              539.57                  9.71                   0.62             549.28        501.81      
      Provision for Taxation                
           Income tax - Current year                63.00                17.00                 11.00               80.00          90.00      
                             - Fringe Benefit Tax                  3.13                  2.73                   1.00                 5.86            2.00      
                             - Earlier years                  0.12               (31.60)                   8.70             (31.48)          18.57      
           Deferred Tax                41.02                15.11               111.48               56.13          84.13      
           Wealth Tax                      -                    0.29                   0.26                 0.29            0.26      
      Profit / (Loss) after Tax              432.30                  6.18              (131.82)             438.48        306.85      
                 
      Paid-up Equity Share Capital 2600.50 2600.50 2600.50 2600.50 2600.50      
      (face value Re. 1/- per Share)                
                       
      Reserves excluding Revaluation Reserve                      -                        -                         -            1,521.31     1,234.95      
                       
      Basic and Diluted Earnings Per Share (Rs.)                  0.17                  0.01                  (0.05)                 0.17            0.12      
                       
      Aggregate of Non-Promoter Shareholding                
      Number of shares 194205340 194205340 194205340 194205340 194205340      
      Percentage of Shareholding 74.68% 74.68% 74.68% 74.68% 74.68%      
               
      Note :        
      1. The Company operates only in one business segment namely  formulations.        
      2. Previous period's figures have been regrouped / rearranged  wherever necessary to confirm to the current periods classification.      
      3. The Board of Directors have recommended a dividend of 5% subject to the approval of members.        
      4. The above results were reviewed by the audit committee and taken on record at the meeting of the Board of Directors held on June 29, 2007.    
      5. During the quarter 5 investor complaints were received and disposed off.  There were no investor complaints pending for the      
         redressal as at the commencement and end of the quarter.        
               
      Chennai - 600 084     For ARVIND REMEDIES LTD.    
      Date: June 29, 2007        
               
            Dr. B Arvind Shah      
              CEO and Managing Director